Department of Hematology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China.
Department of Science and Education, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China.
Int J Clin Pract. 2022 Dec 7;2022:2637581. doi: 10.1155/2022/2637581. eCollection 2022.
To explore clinical features and prognostic value of vascular endothelial growth factor (VEGF), interleukin (IL) 8, IL-10, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and receptor-interacting protein-2 (RIP2) in diffuse large B-cell lymphoma (DLBCL).
A total of 68 DLBCL patients admitted to the Affiliated Hospital of Hebei Engineering University from January 2017 to June 2021 were included in this retrospective analysis. Serum VEGF was detected by enzyme-linked immunosorbent assay, serum IL-8 and IL-10 were detected by chemiluminescent enzyme immunoassay, and expression of PIK3CA and RIP2 in tumors was detected by immunohistochemistry. The correlation between clinical features of DLBCL and tumor-related index were analyzed. Cox regression was conducted to explore risk factors and hazard ratio.
The serum level or expressions of VEGF, IL-8, IL-10, and RIP2 were significantly elevated with the increase of Ann Arbor Stage, International Prognostic Index (IPI) scores, Eastern Cooperative Oncology Group (ECOG) scores, serum lactate dehydrogenase (LDH) level, and the number of extranodal sites (all < 0.05). Beside, these serum indexes were significantly higher in patients with the presence of extranodal involvement and germinal center B-cell (GCB), but significantly lower in patients with the presence of bone marrow involvement (all < 0.05). Cox regression analysis for overall survival revealed that high expression of VEGF, high level of serum IL-8, serum IL-10, and RIP2, Ann Arbor Stage (III-IV), number of extranodal sites (>1), serum LDH level (≥245 U/L), IPI scores (3-5), ECOG scores (≥2), and bone marrow involvement were independent risk factors for the prognosis of DLBCL patients (all < 0.05).
The serum levels of VEGF, IL-8, and IL-10, as well as the expression of RIP2 and PIK3CA in tumor tissues, were highly correlated to clinical features of DLBCL, and high expression level of these indexes may have adverse effects for the prognosis of DLBCL patients.
探讨血管内皮生长因子(VEGF)、白细胞介素(IL)8、IL-10、磷脂酰肌醇-4,5-二磷酸 3-激酶催化亚单位α(PIK3CA)和受体相互作用蛋白-2(RIP2)在弥漫性大 B 细胞淋巴瘤(DLBCL)中的临床特征和预后价值。
回顾性分析 2017 年 1 月至 2021 年 6 月河北工程大学附属医院收治的 68 例 DLBCL 患者。采用酶联免疫吸附试验检测血清 VEGF,化学发光酶免疫分析法检测血清 IL-8 和 IL-10,免疫组织化学法检测肿瘤组织中 PIK3CA 和 RIP2 的表达。分析 DLBCL 患者临床特征与肿瘤相关指标的相关性。采用 Cox 回归分析探讨危险因素和危险比。
血清 VEGF、IL-8、IL-10 和 RIP2 水平或表达随着 Ann Arbor 分期、国际预后指数(IPI)评分、东部合作肿瘤组(ECOG)评分、血清乳酸脱氢酶(LDH)水平和结外受累部位数的增加而显著升高(均<0.05)。此外,这些血清指标在有结外受累和生发中心 B 细胞(GCB)的患者中明显升高,但在有骨髓受累的患者中明显降低(均<0.05)。总生存的 Cox 回归分析显示,VEGF 高表达、血清 IL-8、IL-10 和 RIP2 水平高、Ann Arbor 分期(III-IV)、结外受累部位数(>1)、血清 LDH 水平(≥245 U/L)、IPI 评分(3-5)、ECOG 评分(≥2)和骨髓受累是 DLBCL 患者预后的独立危险因素(均<0.05)。
血清 VEGF、IL-8 和 IL-10 水平以及肿瘤组织中 RIP2 和 PIK3CA 的表达与 DLBCL 的临床特征高度相关,这些指标的高表达水平可能对 DLBCL 患者的预后产生不利影响。